Le congrès inaugural de la Société Européenne d’Inflammation Oculaire (EUSOI) aura lieu à Paris le 4 et le 5 septembre prochain au NOVOTEL Paris Centre Tour Eiffel, 61 quai de Grenelle, 75015, Paris
Vous trouverez ci-joint le programme scientifique et je remercie celles et ceux d’entre vous qui ont accepté d’y contribuer
L’inscription est gratuite mais obligatoire sur le site internet officiel : eusoi.org (attention, le nombre de places est limité)
Ce congrès remplacera C3 qui se tiendra ultérieurement sous la forme d’un webinar inaugurant la mise à jour du PNDS Uvéite et dont la date vous sera communiquée prochainement
En espérant vous retrouver nombreux à Paris début septembre pour cette édition exceptionnelle
Pr Bahram Bodaghi
Pour télécharger le programme :
Programme :
Friday 4 September 2026
11:30 – 12:30
Registration
Foundations and Current Practice
12:30 – 12:45
Welcome and Opening Remarks
Carlos Pavesio President, EUSOI
Objectives of the Society
Vision for European Collaboration in Ocular Inflammation
12:45 – 13:45
Session 1: Systemic Therapy in Uveitis – The European Perspective Joke de Boer (The Netherlands) and Gilles Kaplanski (Marseille)
Benefits and risks of corticosteroids in uveitis Natasa Vidovic (Slovenia)
Efficacy of DMARDs in uveitis Mirjam van Velthoven (The Netherlands)
Treatment of uveitis in the era of biologicals, perspective of the new generation ophthalmologists Charlotte van Meerwijk (The Netherlands)
Early or late start with start biologicals? Perpective of a senior ophthalmologist.
Marc de Smet (Switzerland)
Discussion
13:50 – 14:50
Session 2: Local Therapies in Uveitis Carlos Pavesio (UK), Ahmed Abu El Asrar (Saudi Arabia)
(10-min keynote + 3 cases + discussion)
Keynote – Piergiorgio Neri (UAE)
Case 1- Management of UME – Alessandro Invernizzi (Italy)
Case 2- Management of PIC/MFC – Ilaria Testi (UK)
Case 3- Management of Retinal Vasculitis – Elisabetta Miserocchi (Italy)
Discussion
14:55-15:15
Industry Symposium – Agephapharma
Ultracortenol (prednisolone pivalate 5 mg/g) and its role in the management of ocular inflammation Yosuf El Shabrawy (Austria)
15:20 – 16:20
Coffee Break
16:25 – 17:25
Session 3: Complex Decision-Making in Uveitis Sofia Androudi (Greece) and Jarmila Heissigerova (Czech Republic)
(10-min keynote + 3 cases + discussion)
Keynote – Diagnostic strategies in complex uveitis Sara Touhami (France)
Case 1 – Masquerade syndrome Zohar Habot-Wilner (Israel)
Case 2 – Autoimmune uveitis Ioannis Papasavas (Switzerland)
Case 3 – Infectious uveitis Aniruddha Agarwal (UAE)
Discussion : Siham Chariba (Marocco), Cherif Titah (France), François Willermain (Belgium)
17:30-18:30
Industry Symposium – Founding Sponsor Symposium, Roche
18:30 Welcome reception
Saturday 5 September 2026
Advanced Therapies, Imaging and the Future
08:30 – 09:30
Session 4: Biologic Therapy in Uveitis Bahram Bodaghi (France) and David Saadoun (France)
(10-min keynote + 3 cases + discussion)
Keynote : Biotherapies in Uveitis : update and perspectives D. Saadoun (France)
Case 1 : Ines Leal (Portugal)
Case 2 : Anne-Claire Desbois (France)
Case 3 : William Tucker (UK)
Discussion : Marie-Josée Aubin (Canada), Mathilde Leclercq (France), Yosuf El Shabrawy (Austria)
09:35 – 10:35
Session 5: Imaging in Ocular Inflammation Elisabetta Miserocchi (Italy) + Bahram Bodaghi (France)
Multimodal imaging in posterior uveitis Luca De Simone (Italy)
OCT biomarkers of inflammatory activity Prithvi Ramthoul (France)
Widefield angiography and retinal vasculitis Ester Carreno (Spain)
Choroidal imaging (EDI-OCT, ICGA) Maria Vittoria Cicinelli (Italy)
Imaging endpoints in clinical trials Alessandro Marchese (Italy)
Discussion Marie-Hélène Errera (USA)
10:35 – 10:55
Coffee Break
10:55 – 11:55
Session 6: Orbital Inflammation optic neuritis and Scleritis Carlos Pavesio (UK) Valérie Touitou (France)
- Thyroid eye disease Jimmy Uddin (UK)
- IgG4-related orbital disease Federico Maestri (France)
- Necrotising and non-necrotising scleritis Julie Gueudry (France)
- Noninfectious optic neuritis Valerie Touitou (France)
- Multidisciplinary management (ophthalmology + rheumatology)
Panel discussion : Isabelle Hardy (Canada), Sebastien Abad (France)
11:55 – 12:55
Session 7: Ocular Surface Inflammation and Dry Eye. Christophe Baudouin, (President of the European Dry Eye Society) Dry eye in autoimmune disease
- Inflammation as a central mechanism of dry eye, Christophe Baudouin (France)
- Digital screen use in children : challenges for myopia progression and ocular surface, Dominique Bremond-Gignac (France)
- Biomarkers in ocular surface inflammation : challenges and usefulness, Marlies Gijs (The Netherlands)
- The role of microbiota in dry eye disease, Marc Labetoulle (France)
Discussion
13:00 – 14:00 Lunch
14:00 – 15:00
Industry Symposium – Founding Sponsor Symposium, Alimera
Long-Acting Intravitreal Therapy in Non-Infectious Uveitis
Optimising Outcomes with Iluvien
15:00 – 16:00
Session 8: Emerging Therapies and the Pipeline Alex Fonollosa (Spain) + David Saadoun (France)
Multidisciplinary session with internists and rheumatologists
- Introduction: Precision Immune Modulation in Uveitis Colin Chu (UK)
- Targeting ERAP to treat uveitis in the MHC-I-opathies. Jonas Kuiper (Netherlands)
- Brepocitinib – TYK2/JAK1 inhibition Elena Bolletta (Italy)
- Bimekizumab – Dual IL-17A/F inhibition Carmen Secada (Spain)
- Port-Delivery Platform (PDP): Sustained Intraocular Drug Delivery Aude Couturier (France)
Panel Discussion: Luca Cimino (Italy), Abdulrahman Albloushi (Saudi Arabia)
16:05 – 17:05
Session 9: European Research Priorities and Collaborative Strategy Pre-Prepared Strategic Working Session Talin Barisani (Austria), Marc De Smet (Switzerland)
Pre-Meeting Work:
- European-wide survey
- Priority theme identification
- Rapporteur concept briefs
- Draft proposals circulated in advance
Session Structure:
- Summary of survey findings
- Focused topic presentations
- Structured breakout discussions
- Consensus vote and action plan
Deliverable: Defined EUSOI Research Roadmap 2026–2028
17:10 – 18:00
Session 10: EUSOI Society Session (45 Minutes) Executive Board
- Summary of strategic outcomes
- Governance and committee structure
- Education and fellowship initiatives
- Strategic roadmap 2026–2028
- Member engagement and future meetings
18:00
Closing Remarks